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EDITORIAL REVIEW
The erythrocyte—immune complex—glomerulonephritis
connection in man
Over the past five years there has been a groundswell of
evidence from numerous laboratories indicating that the eryth-
rocytes of humans and other primates may play a key role in the
handling of immune complexes (IC) in the circulation. Most of
this work has been reported outside the traditional nephrology
literature and, to date, there has been no comprehensive review
of this rapidly expanding subject from the nephrology perspec-
tive. However, there have been two excellent reviews stressing
the basic immunology aspects of this topic [1, 2]. It is the goal
of this review to examine the experimental evidence suggesting
an important role for erythrocyte/IC interactions in the primate
and to discuss their potential clinical implications.
The erythrocytes of man and other primates appear to play a
key role in the handling of circulating IC by providing a
"clearing" mechanism and a "processing" mechanism. The
essential first step in the handling of IC by the erythrocyte is the
binding of the IC to the erythrocyte. Once bound to the
erythrocyte, the evidence indicates that the IC can then be
transported to liver and spleen for safe disposal (the "clearing"
function of the erythrocyte). IC bound to the erythrocyte may
also be acted on by specific plasma components which alter the
IC and cause the IC to be released from the erythrocyte (the
"processing" function of the erythrocyte). Released IC may
have reduced pathogenicity and may provide a signal to the
immune system. Although the biological importance of the IC
"clearing" and "processing" function of the primate erythro-
cyte remains to be proven, the evidence accumulated to date
strongly suggests that the normal operation of these erythrocyte
functions may be important in protecting against the develop-
ment of IC-mediated disease.
Binding of IC to primate erythrocytes
More than 30 years ago, Nelson recognized that the erythro-
cytes of humans and other primates were able to bind opsonized
IC via what they termed an "Immune Adherence" (IA) recep-
tor [3]. It is now recognized that the IA receptor is a comple-
ment receptor Type 1 (CR1). CR1 has its natural ligand C3b, the
major fragment of the activated third component of complement
(C3). Thus, in order for IC to bind to primate erythrocytes the
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IC must be capable of activating and fixing C3b.' CR1 also
recognizes C4b but the binding affinity for C4b is only about
one-tenth that of C3b [10]. In primates, CR1 is present on
erythrocytes, neutrophils, monocytes, B-lymphocytes, some T
lymphocytes, eosinophils, mast cells and glomerular epithelial
cells [1, 2]. Free CR1 is also present in small amounts in plasma
[11]. CR1 on erythrocytes is present in relatively low concen-
trations compared to blood leukocytes. The approximate mean
number of CR! per cell is: erythrocytes 500; neutrophils 20,000;
B-lymphocytes 21,000; and monocytes 30,000. However, since
there are far more erythrocytes than leukocytes in the circula-
tion in primates, over 85% of all CR! in the circulation are
erythrocyte CR1 [1, 2].
The CR1 is a single polypeptide chain ranging in size from
160,000 daltons to 260,000 daltons. The size of the CR1 chain
appears to be determined genetically, as is the average number
of erythrocyte CR1 [1, 2]. As discussed below, other factors
may also affect erythrocyte CR! levels.
Figure 1 (Steps 1 and 2) shows schematically how the binding
of IC to erythrocyte CR1 is thought to occur. Antibodies which
are properly spaced on the antigen will permit the binding of Cl
(q + r2 + s2) to the antibodies. Once Cl is bound, the classical
pathway C3 convertase, C4a,2b, is assembled. The C4a,2b
complex then begins cleaving fluid phase C3 into C3a and C3b.
This activates a labile thioester bond on the C3b fragment
permitting the C3b molecule to bind covalently to certain sites
on the antibody or antigen. Even more C3b molecules can be
generated when the alternative pathway C3 convertase, C3bBb
is formed. As a result of the combined actions of these C3
convertases, C3b molecules may be deposited at many different
sites on the IC. In addition, some C3b molecules will bind CS,
changing its conformation and resulting in proteolytic cleavage
of CS to C5a and C5b by both C3 convertases: C4b,2a and
There are reports that primate erythrocytes can bind immune
complexes by noncomplement—mediated mechanisms [4—6], possibly
Fc receptors (FcR). There are also reports that under some circum-
stances, nonprimate erythrocytes may exhibit IA-like activity (that is,
bind IC by complement mediated mechanisms) [7]. However, when the
IC binding capacity is directly compared for primate and nonprimate
erythrocytes, the nonprimate erythrocytes have little or no capacity to
bind IC, with or without complement, and primate erythrocytes have
little or no capacity to bind IC without complement [8, 9]. Thus, if FcR
are present on primate erythrocytes or CR1 are present on nonprimate
erythrocytes, they are probably present in small numbers.
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C3bBb. C5b has specificity for C6. Activation of the remaining
components (C5 to C9) results in the activation of the mem-
brane attack complex (MAC) (C5b-C9) [12].
In order for the IC to achieve binding to the erythrocyte, the
IC must be able to activate the complement cascade and bind
C3b molecules (as described above). In addition, the IC must be
of sufficient size [8, 13]. In general, large IC bind to erythro-
cytes better than small IC, but the critical size necessary to
achieve IC binding to erythrocytes is dependent upon the
specific antigen—antibody system [14]. The reason for the better
binding of large IC to erythrocytes is not certain but it is likely
that the greater ability of large IC to activate complement [13] is
an important factor. In addition, the larger IC should be more
likely to achieve multipoint binding to the relatively sparse
erythrocyte CR!. This is probably an important issue because
multipoint binding of IC to cells is more stable than single point
binding [15]. It is possible that CR! can move within the
erythrocyte membrane [16] to enhance the likelihood of
multipoint binding, as can occur in macrophages, however, that
remains to be proven. Formation of IC in antibody excess also
enhances IC to erythrocyte binding [14] as does the use of large
antigens [17]. Other biophysical properties of IC may also affect
the ability of IC to bind to erythrocytes. However, at present
these factors are poorly understood.
The primate erythrocyte IC clearing mechanism
We have demonstrated that when complement fixing IC are
infused into the circulation of normal, nonhuman primates,
within one to two minutes the majority of the IC will become
bound to circulating erythrocytes. The remaining IC will be free
in the plasma or bound to leukocytes [18, 19]. The IC bound to
erythrocytes do not deposit in organs such as kidney. This is
shown by the fact that the percent of IC bound to erythrocytes
entering kidney (renal artery) is the same as that exiting kidney
(renal vein). By contrast, when these IC-bearing erythrocytes
traverse liver, the IC are rapidly stripped from the erythrocyte
and deposited in liver. The erythrocyte then returns to the
circulation [18, 19], apparently able, once again, to participate
in this "erythrocyte-IC clearing mechanism." The spleen ap-
pears to function in the same manner as liver with respect to the
erythrocyte-IC clearing mechanism [18, 19]. A schematic rep-
resentation of the erythrocyte-IC clearing mechanism is shown
in Figure 1.
The binding of IC to erythrocytes in vivo is complement
mediated just as it is in vitro. This is shown by the fact that in
nonhuman primates, complement depletion by intravenous
infusion of cobra venom factor (CVF) or complement inhibition
by intravenous infusion of high—dose heparin, abrogate binding
of IC to erythrocytes in vivo [19].
Mechanism of hepatic and splenic uptake of IC bound to
erythrocytes
The stripping of IC bound to erythrocytes by liver and spleen
can be viewed as occurring in two steps: 1) the IC on the
erythrocyte must become bound to an hepatic or splenic
macrophage and 2) the bond between the IC and the erythro-
cyte must be broken, allowing the erythrocyte to return to the
circulation.
With regard to the first step, it is not certain how the
macrophage recognizes the IC bound to the erythrocyte, but it
seems likely this recognition occurs largely through macroph-
age FcR. The evidence for this is that complement depletion in
primates does not affect IC uptake by liver [19]. If hepatic IC
uptake were dependent upon the binding of C3b opsonized IC
to hepatic macrophage complement receptors, we would have
expected to see depressed IC uptake under the conditions of
complement depletion. Further evidence for hepatic macroph-
age FcR binding of IC bearing erythrocytes is that attempts to
blockade hepatic FcR by infusion of aggregated human IgG
(AHIgG) directly into the portal vein markedly impairs hepatic
uptake of IC bound to erythrocytes. An experiment demon-
strating this phenomenon is shown in Figure 2. In this experi-
ment (representative of two experiments) the removal of IC
from erythrocytes traversing liver was markedly impaired after
the infusion of AHIgG. Some of this impairment of hepatic IC
uptake could have been due to hepatic macrophage CR! block-
ade by opsonized AHIgG. However, it seems unlikely that this
is a major mechanism since, as noted above, even profound
complement depletion, which should maximally interfere with
hepatic IC uptake by C3b mechanisms, does not affect overall
hepatic uptake [19]. Thus, the accumulated evidence suggests
that in primates, hepatic uptake of IC bound to erythrocytes is
largely mediated by hepatic macrophage FcR.
The mechanism of the second step in the hepatic uptake of
IC, the breaking of the bond between the IC and the erythro-
cyte, is less clear. Nevertheless, it appears that the mechanism
is swift. This is suggested by the fact that when IC are infused
into the circulation of primates in which the erythrocytes have
been labeled with 51Cr, there is no sign of hepatic retention of
the IC-bearing 51Cr-labeled erythrocytes [18] as the IC are
stripped from the erythrocyte in liver. That is, the 5tCr concen-
tration in hepatic vein blood and arterial blood are the same. If
substantial numbers of t1Cr-labeled erythrocytes were being
temporarily detained in the liver during the stripping process, a
transient decrease in 51Cr CPM in hepatic vein blood might have
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Fig. 1. Schematic representation of the operation of the primate
erythrocyte-IC clearing mechanism.
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Fig. 2. Clearance of IC from the circulation of a baboon before (0) and
after (•) infusion of aggregated human IgG (AHIgG) into the portal
vein at a dose calculated to achieve blockade of hepatic FcR. Under
general anesthesia and with the use of fluoroscopy, the catheters were
placed in the following sites: ascending aorta (for infusion of IC),
abdominal aorta (for arterial blood sampling), and the hepatic, renal and
portal veins (for venous blood sampling). The portal vein catheter was
also used for infusion of the AHIgG. All of the above techniques have
been described previously [18, 19]. Using our standard protocol, the
clearing of an IC probe (mouse monoclonal IgGl anti-DNP-'251-labeled
DNP BSA was assessed before and 3 minutes after infusing 2 g of
AHIgG over 2 mm into the portal vein. The resulting 1251 levels in blood
are shown above. Relevant data not shown above are: peak % IC
binding to E in arterial blood (Pre-AHIgO: 82%, post-AHIgG, 68%,
peak binding was observed at 120 sec after the start of the respective IC
infusions); % of IC removed from arterial blood erythrocyte during
passage through liver (pre-AHIgG: 94%, post-AHIgG: 36%. These are
the mean of the values observed at 90, 120, 150 and 180 sec after the
start of the respective IC infusions). These data show that hepatic-IC
uptake was markedly impaired after a blocking dose of AHIgG was
infused into the portal vein. This impaired hepatic IC uptake was due to
a marked decrease in hepatic IC uptake from plasma and from
erythrocytes.
been observed during the height of the stripping process. This,
however, was not observed [18, 191.
It is possible that the swift release of the erythrocyte from the
macrophage bound IC is mediated by enzymatic mechanisms.
Indeed, it has been shown that macrophages can efficiently
remove IC bound to the surfaces of B cells by phagocytosis of
the IC which are bound to the B cell by receptors which have
undergone capping [20]. It is also possible that the transfer of IC
from erythrocyte to hepatic macrophage is largely a mechanical
event. This hypothesis requires that the total force of binding of
the IC to the erythrocyte CR! is less than the total force of
binding of IC to hepatic macrophages FcR. This seems to be a
reasonable assumption since the density of FcR on hepatic
macrophages is much greater than the density of CR! on
erythrocytes [1, 2]. Thus, the IC should be able to achieve
greater levels of multipoint binding to the hepatic macrophage
compared to the erythrocyte. If this is the case, when the
erythrocyte breaks free from its attachment to the tissue-bound
macrophage, it will leave the IC behind, bound to the hepatic
macrophage. The breaking free of the erythrocyte from the
tissue-bound macrophage should be aided by the fact that the
erythrocyte is relatively rigid and, therefore, can act as a sail
upon which the hydrostatic pressure of blood flow is applied to
provide the force necessary for the erythrocyte to break free
form its attachment to the IC.
Evidence that the binding of IC to erythrocytes prevents IC
uptake by vulnerable organs such as kidney, but promotes IC
uptake by liver and spleen
The results of our original study describing the erythrocyte-
IC clearing mechanism [18] suggested that the binding of IC to
erythrocytes in the circulation served to prevent the deposition
of IC in organs, such as kidney, and to promote the safe
deposition of IC in liver and spleen. It was possible, however,
that the binding of the IC to erythrocytes had no effect on the
ultimate fate of the IC in the circulation. That is, although it had
been demonstrated that IC bound to erythrocytes did not
deposit in kidney, it was possible that the IC bound to eryth-
rocytes would not have deposited in the kidney, even if the IC
had been free in the plasma. If that were the case, it would also
follow that the IC which were bound to erythrocytes and which
were eventually deposited in liver and spleen would have
deposited there, whether or not the IC had been bound to E. To
test the hypothesis that the binding of IC to E prevents IC
deposition in organs such as kidney, but promotes safe disposal
of IC in liver and spleen, two additional series of experiments
were undertaken.
In the first series of experiments, the clearance from the
circulation and tissue uptake of BSA-rabbit anti-BSA IC was
examined in nonhuman primates under conditions in which IC
to E binding proceeded normally or was prevented by systemic
complement depletion with either intravenous CVF or intrave-
nous high—dose heparin treatment. These experiments showed
that, compared to the complement—replete state, under condi-
tions of complement depletion, IC clearance from the circula-
tion occurred more rapidly (peak IC clearance was approxi-
mately three times faster) and the increased rate of IC uptake
was accounted for almost entirely by an increase in IC uptake at
nonhepatic, nonsplenic sites [19]. Thus, an important effect of
IC-to-erythrocyte binding on the clearance and tissue uptake of
IC in the primate was demonstrated.
To explore this issue further, in a second series of experi-
ments the fate of two different IC probes, one of which bound
well in vitro to primate erythrocytes (mouse monoclonal IgGl
anti-DNP-IC) and the other which did not bind well in vitro to
erythrocytes (mouse monoclonal IgA-anti-DNP-IC), were stud-
ied [2!]. These IC probes were injected simultaneously or
sequentially into the circulation of nonhuman primates. We
Arterial blood
0
o.
.0
.0
.
0
Hepatic vein blood
.
.
.
. .
.
o0 00 0 0
24
20
16
12
8
4
24
20
16
12
8
4
00
.0
at
0I
E
to
0
at
a,
.0
at
-J
•0
Renal vein blood Portal vein blood0
.
00
0 c. 00
• 0.8 o.
• 00 0 0
.
•
.0
880 Hebert and Cosio
found that, compared to the IgGI-IC, the IgA-IC (the IC probe
which bound less well to erythrocytes):
1. Were cleared more quickly from the circulation
2. Showed enhanced nonhepatic, nonspienic uptake (espe-
cially lung, whole renal cortex and glomeruli) and
3. Showed diminished uptake by liver and spleen.
The differential fate of the IgA-IC versus the IgG 1-IC could
not be explained by differences in size, charge or antibody
affinity, the biophysical properties of IC which are currently
recognized as being the factors determining IC clearance from
the circulation and tissue uptake.
The differences in clearance from the circulation and tissue
uptake between IgA-IC versus IgG 1-IC seem best explained by
the fact that the IgA-IC bound less well to circulating erythro-
cytes. Similarly, the effects of complement depletion on IC
clearance and tissue uptake [191 also can be best explained by
the effect of complement depletion to decrease the binding of IC
to erythrocytes.
Based on the experiments described above [18, 19, 211, there
now appears to be sufficient evidence to formulate a general
hypothesis concerning the role of IC-to-erythrocyte binding as
a determinant of the fate of IC in the circulation of primates: IC
that do not bind well to circulating erythrocytes will tend to be
free in the plasma, and for this reason are more susceptible to
depositing in tissue than are IC which are bound to erythro-
cytes. Thus, all other factors held constant, conditions which
lead to decreased binding of IC to erythrocytes in vivo should
lead to the following predictable consequences.
Accelerated clearance of IC from the circulation. This is
because IC free in the plasma are susceptible to uptake by liver
and spleen plus all other sites in the circulation; by contrast, IC
bound to erythrocytes are susceptible to uptake mainly by liver
and spleen. Since splenic and hepatic blood flow combined are
only about 22% of cardiac output2 many circuits of the vascular
system will be required before IC bound to erythrocytes can be
removed from the circulation. Thus, conditions which promote
binding of IC to erythrocytes should delay the clearance of IC
from the circulation. On the other hand, conditions which
inhibit binding of IC to erythrocytes should accelerate the
clearance of IC from the circulation.
Diminished IC uptake by liver and spleen. Because decreased
binding of IC to erythrocytes leads to increased uptake of the IC
dose at nonhepatic, nonsplenic sites in the circulation, less IC is
available for deposition in liver and spleen.
Enhanced IC uptake by lung and kidney. Of the major organ
systems, lung and kidney have the highest blood flow per gram
of tissue3, These organs will have the highest rates of contact
between circulating IC and the vascular endothelium. Thus,
lung and kidney should be the major nonhepatic, nonsplenic
sites of IC uptake.
All of the data obtained thus far on the primate erythrocyte-
2This estimate of splenic and total hepatic (hepatic artery + portal
vein) blood flow is based on unpublished microsphere blood flow
studies, performed under experimental conditions comparable to the
present study, in the dog and the baboon [18].
kidney is approximately 0.4% of body weight but receives
approximately 25% of cardiac output. The lung is approximately 2.5%
ofbody weight but receives 100% of cardiac output.
IC clearing mechanism[18, 19, 21, 22] are consistent with the
above hypothesis. It must be recognized, however, that the
above studies do not establish whether or not the IC cleared by
the erythrocyte-IC clearing mechanism are representative of
the IC capable of causing glomerulonephritis.
Antibody homology and the operation of the erythrocyte-IC
clearing mechanism
The operation of the primate erythrocyte-IC clearing mech-
anism has been elucidated using an heterologous system [18, 19,
21]. That is, the IC were composed of rabbit or mouse antibody
and their fate was examined in the primate. However, we
recently completed a study in collaboration with Dr. Ronald
Taylor of the University of Virginia in which we used an IC
probe composed of human antibody to DNA and PM2dsDNA
[9] to study the operation of the erythrocyte-IC clearing mech-
anism in the nonhuman primate (baboon). We found that the
operation of the erythrocyte-IC clearing mechanism using the
IC composed of primate antibody was qualitatively the same
[221 as when using a IC composed of nonprimate antibody [18,
19, 21].
In summary, a substantial body of evidence now exists
suggesting that primates possess an erythrocyte-IC clearing
mechanism which is swift, efficient and is capable of preventing
IC deposition in vulnerable locations such as kidney, but
capable of enhancing safe disposal of IC in liver and spleen. The
erythrocyte-IC clearing mechanism appears to be designed to
complete its task within minutes. That is, in vivo, an IC capable
of activating complement can be opsonized sufficiently within
one minute to bind to erythrocytes. Once bound to the eryth-
rocyte, in the normal course of events, the IC would be
removed from the circulation within a matter of a few more
minutes. If the removal of the IC from the erythrocyte cannot
be accomplished within these few minutes, it appears that the
primate has a second option in which the IC may be "proc-
essed" on the erythrocyte membrane rendering the IC less
pathogenic and, perhaps, rendering the IC capable of providing
immunologic signals to the cellular immune system. The eryth-
rocyte-IC processing mechanism appears to work more slowly
than the erythrocyte-IC clearing mechanism [23—26]. For this
reason, "clearing" may be the first option for handling IC in the
circulation of primates while "processing" may be the second
option.
The primate erythrocyte processing of C3b-IC
The essential first step in the processing of IC by erythrocytes
is the binding of the IC to the erythrocyte. Since these IC may
still be capable of activating complement, the surface of the
erythrocyte may become exposed to the products of comple-
ment activation. The erythrocyte cell membrane seems espe-
cially well adapted to protect itself against injury by the
products of complement activation. That is, CR1 can inhibit the
complement cascade by increasing the degradation of C3b [27].
Decay accelerating factor (DAF) leads to accelerated decay of
the classical pathway convertase by interfering with the activity
of C4b [28, 29]. Finally, glycophorin alpha, a ubiquitous protein
in the red cell membrane, has the ability to bind C3b and may
also protect the red cell from complement—mediated injury [30].
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C3 and its degradation products
Fig. 3. Schematic representation of C3 and its degradation products.
This figure is an adaptation of material published previously by Aranout
and Colton [1] and Ross et a! [32].
Thus, the primate red cell appears to be well adapted to its role
as a site for processing of IC capable of activating complement.
The processing of the IC bound to the erythrocyte membrane
appears to involve two distinct operations:
Factor I mediated cleavage of C3b causes the IC to be
altered and released from the erythrocyte
In the fluid phase, C3b degradation is accomplished by Factor
I with Factor H serving as the cofactor [12]. However, when
C3b is bound to CR1, as in the case of C3b bound to IC, the
erythrocyte CR1 acts as a cofactor for Factor I. With CR! as
cofactor, Factor I-mediated cleavage of C3b proceeds i0 to io
times faster than with Factor H as cofactor [311. Figure 3 shows
the steps involved in C3 degradation. As can be seen, the end
product of Factor I-mediated C3b degradation is C3d-g, which
will not bind to CR!. Thus, the IC which have been bound to
erythrocyte CR1, via C3b, will now be released. However, the
C3d-g will remain covalently bound to the IC. The C3d-g site on
the IC can then be degraded to C3d by a variety of nonspecific
proteases present in blood. The IC with C3d sites exposed are
now able to bind to CR2 receptors which are present on
B-lymphocytes [331.
The complement system acts upon IC bound to erythrocytes
causing the IC to be altered and released from the
erythrocyte
Intercalation of C3b into the lattice of the IC results in
disruption of the IC lattice with the production of smaller
complexes. This can result in solubilization of an immune
precipitate [34]. This complement—mediated solubilization can
proceed entirely by the action of the alternative pathway but is
accelerated by simultaneous activation of the classical comple-
ment pathway [34]. Complement activation on IC bound to the
membranes of lymphocytes or erythrocytes can result in the
release of the IC from the cell surface. In some studies, the
released IC are reduced in size [35]. In other studies, the
released IC are not importantly changed in size [36, 37]. Our
experience studying IC formed from specific monoclonal anti-
body preparations supports the latter findings (unpublished
observations). The mechanism by which complement activation
releases IC from cell surfaces is not clear. However, if comple-
ment activation results in disruption of the IC lattice and the
formation of multiple small IC bound to the cell surface, it is
possible that the mechanism of IC release is a decrease in the
number of binding sites per intact IC. Thus, the total force
causing a given IC to be bound to the cell surface would be less,
permitting the IC to be released.
The relative importance of Factor I versus complement—
mediated release of IC from cell membranes is not clear.
However, it is possible that it depends upon the type of IC being
acted upon. For example, Medof, Prince and Mold have shown
that Factor I is effective in releasing rabbit-anti-BSA IC from
the surface of human erythrocytes [38]. However, Taylor has
found that Factor I is less effective in releasing human anti-
DNA-viral DNA IC bound to erythrocytes [36].
The possible biological effects of processing of IC are as
follows:
Processed IC may be rendered less pathogenic. This may
come about in two ways: a) Processed IC may be reduced in
size through the action of intercalation of C3b into the IC
lattice, as discussed above. Smaller IC have a lesser capacity to
deposit in tissue and have a lesser capacity to incite inflamma-
tion [39].
b) Processed IC may have lost their capacity to activate the
complement cascade. This may come about because of reduced
IC size, as noted above, but also because the CR1-bound C3b
sites on the IC are degraded through the action of Factor I.
Thus, activation of the terminal complement components (CS to
C9) is prevented because both classic (C4b,2a,3b) and alterna-
tive (C3b,Bb,3b) CS convertases require intact C3b. In addi-
tion, the classical pathway C3 convertase, C4b,2a is also bound
to CR! and degraded by Factor I thus preventing further C3
activation through this convertase. In effect, processing "dis-
arms" the IC. The disarming of the IC is probably a cyclic
process, as suggested in Figure 4, particularly for those IC
which must remain in the circulation because they cannot be
readily cleared from the circulation and safely deposited in liver
and spleen.
The processed IC may be capable of generating immunologic
signals to the immune system. As discussed above, C3b sites
bound to CR! are degraded by Factor Ito C3d-g. C3d-g can be
further degraded to C3d which can then bind to CR2 which are
present on immune cells. Limited evidence indicates that the
binding of C3d to B-cells is immunosuppressive by inhibiting
B-cell and T-cell proliferation and differentiation [33, 40].
Factor I can also degrade C3 to C3bi which permits the IC to
bind to spleen cells [41]. Thus, it is possible that the binding of
C3d and C3bi bearing IC to immune cells is an immunologic
signal.
Figure 5 provides a description of the possible pathways of IC
handling in the primate. The pathways designated by the
heavier arrows represent our interpretation of the natural and
preferred pathway of IC management. The lighter arrows
131 75Kd I
S
S
___at - l2OKd I
C3
I I—
S S9KdJ r11OKd _______
C3a Ô=O C3b
—
H,3R
—
S S
S S3Kd D E68 KdJ 43Kd
S C=O C3bi
—
4l Kd]Sc=o +
H
8Kd [31 Kd9 sc=oçH OR
S
127 KdJ
S
e
E43 Kd
C3c
882 Hebert and Cosio
IC is formed in the circulation and activates
complement. C3b sites are generated on IC
IC binds to erythrocyte CR1/
IC is released from
erythrocyte by factor I
degradation of C3b sites
Released IC is
reduced in size and
can no longer
j, // activate complement
IC is nonpathogenic.
Eventually IC is removed
from the circulation,
probably by uptake by
hepatic or splenic
macrophage FcR
IC deposits at nonhepatic
nonsplenic sites, activates
complement and causes injury
IC phagocytosed by
monocytes or neutrophils
IC binds to B-Cells
(causing immunosuppression?)
represent the pathways which may develop in IC-mediated
diseases when, presumably, the erythrocyte-IC clearing mech-
anism and processing mechanism are defective or are unable to
properly handle the IC load.
In summary, in vitro studies have shown that the primate
erythrocyte is highly adapted to serve as the site on which IC
can be altered to either reduce the pathogenicity of the IC, or to
change the IC in such a way that it can then bind to immune
cells and perhaps modify the immune response of those cells.
Although the biological importance of these processing func-
tions of the primate erythrocyte remain to be proven, the in
vitro evidence is impressive that processing could play an
important part in immune regulation and play a key role in
protection against IC-mediated disease.
Clinical implications of erythrocyte-IC interactions
The discovery that complement—mediated binding of IC to
erythrocyte CR! is the essential first step in the operation of an
erythrocyte-IC clearing and processing mechanism may pro-
vide the key to understanding the pathophysiology of several
important IC-mediated diseases. These issues are discussed
below.
N
IC is released from the erythrocyte
through the effects of complement
activation on the IC
New C3b sites are
generated on IC
/
IC is no longer able
to activate complement
Released IC is
still able to
activate complement
IC forms in the circulation
I
IC activates complement and becomes
opsonized with C3b
Fig. 4. Mechanism by which "processing" can
render IC nonpathogenic.
Fig. 5. Possible pathways for the handling of IC
in the circulation of primates.
IC binds to erythrocyte CR1
I
IC is processed
(see Fig. 4)
IC is deposited in liver or spleen
Erythrocyte—immune complex interaction in man 883
Deficiencies of the complement system and IC-mediated
diseases
The complement system generates an inflammatory response
when activated by IC. Thus, it might be expected that patients
with complement deficiency states would be relatively pro-
tected against the development of IC-mediated disease. On the
other hand, deficiency of the complement system could impair
the operation of the erythrocyte-IC clearing and processing
mechanism when the complement deficiencies involve the
classical or alternative pathway components (those components
which mediate binding of IC to erythrocyte-CR1). Thus, if
impairment of erythrocyte-IC interactions is the dominant
effect of deficiency of the classical or alternative pathway
complement components, complement deficiencies should not
protect but should actually predispose to the development of
IC-mediated disease.
On the basis of numerous reports in the literature, it is now
clear that complement deficiency does not protect against
development of IC-mediated disease. In fact, patients with
deficiencies of complement have a remarkably high incidence of
IC-mediated diseases. Schifferli and Peters recently reviewed
this topic [34]. They found that patients with deficiencies of the
classical and alternative pathway complement components
have an extraordinary high incidence of IC-mediated disease.
For example, for patients with individual factor deficiencies of
Clq, Clr or s, C4, C2 or C3, the incidence of associated
IC-mediated disease ranged from 58% (patients with C2 defi-
ciency) to 93% (patients with Clq deficiency). Thus, the patients
with complement component deficiencies which would be ex-
pected to interfere with the operation of the erythrocyte-IC
clearing and processing mechanism are at great risk to devel-
opment of IC-mediated disease. Some of these patients also
have frequent infections. Thus, perhaps in those particular
patients, frequent infections lead to excessive formation of
circulating IC and these IC cannot be efficiently and safely
cleared from the circulation because of the impaired operation
of the erythrocyte-IC clearing and processing mechanism.
It should be noted that frequent infections in patients with
deficiencies of the classical and alternative complement com-
ponents does not, in itself, appear to be an adequate explana-
tion for the increased incidence of IC-mediated diseases in
these patients, because patients with deficiencies of the termi-
nal complement components also have frequent infections, but
the incidence of IC-mediated disease in these patients is low
compared to the patients with deficiencies of the classical and
alternative pathway components. For example, for patients
with individual factor deficiencies of CS, C6, C7, C8 and C9, the
incidence of IC-mediated disease ranges from 8% (C7 defi-
ciency) to 14% (CS deficiency). Perhaps in patients with defi-
ciencies of the terminal complement components the frequent
infections lead to excessive IC formation, but the fact that the
classical and alternative pathway components are intact may
permit more efficient operation of the erythrocyte-IC clearing
and processing mechanism. Thus, for this reason, most of these
patients may be protected from the development of IC-medi-
ated disease.
It has also recently been reported that hydralazine and
isoniazid, drugs commonly associated with drug—induced SLE,
inhibit the activation of C4 [42]. This could inhibit the formation
of the C3 convertase, C4b,2a and lead to impaired function of
the erythrocyte-IC clearing and processing mechanism. Thus, it
is possible that the SLE-like disease observed with the use of
these drugs is explained, in part, by the ability of these drugs to
interfere with the operation of the erythrocyte-IC clearing and
processing mechanism.
Hypocomplementemic membranoproliferative glomerulone-
phritis (MPGN) Type I [43] is another, possibly relevant exam-
ple of how deficiencies of the classical or alternative comple-
ment components might lead to IC-mediated disease. Most
authors would agree that MPGN Type I is an IC-mediated
disease. Some of these patients with hypocomplementemic
MPGN have C3 nephritic factors (C3 NeF), an immunoglobulin
which stabilizes the alternative pathway C3 convertase, C3bBb
[43]. C3 NeF can result in profound and sustained reduction in
serum C3 levels. Perhaps glomerulonephritis develops in these
patients in part because of an inability to efficiently clear or
process IC in the circulation, even those IC which normally and
commonly form after eating, simple infections, pregnancy, etc.
Although the above findings, demonstrating an association
between IC-mediated disease and deficiencies of the classical
and alternative complement pathways, are consistent with the
hypothesis that impairment of the erythrocyte-IC clearing
mechanism may predispose to IC-mediated disease, these ob-
servations are also consistent with the hypothesis put forth by
Schifferli and Peters that normal, classical and alternative
pathway complement activation is necessary to prevent IC
precipitation and to promote IC solubilization [34]. Thus, the
absence of these complement mediated functions may predis-
pose to IC mediated disease. Of course, it is also possible that
both effects of complement depletion (impaired function of the
erythrocyte IC clearing and processing mechanism and im-
paired inhibition of IC precipitation and IC solubilization) are
operational in complement depleted humans and other pri-
mates. Indeed, it would be surprising if this were not the case.
Nevertheless, IC are capable of rapidly forming in the presence
of normal whole blood (that is, IC readily form in the presence
of normal amounts of complement components) and rapidly
bind to erythrocytes [36]. Thus, because of the greater speed of
the erythrocyte-IC clearing mechanism relative to complement—
mediated solubilization of IC, it seems likely that the major
benefit of being normocomplementemic, when IC formation is
occurring, is enhancement of the erythrocyte-IC clearing and
processing mechanisms.
Deficiencies of erythrocyte CR1 and IC-mediated disease
Deficiencies of erythrocyte-CR1 may also predispose to the
development of IC-mediated disease. Perhaps the best exam-
pies are patients with SLE. Recent evidence from numerous
laboratories has shown that patients with SLE have deficiencies
of CR1 both by functional assays (binding of IC or dimeric C3b
to erythrocyte CR1) or antigenic assays (binding of polyclonal
or monoclonal antibodies to erythrocyte CR!) [1, 2].
Generally, SLE patients have CR1 levels 40 to 60% of that of
normal. There appears to be several reasons why SLE patients
express decreased numbers of erythrocyte CR!.
Inheritance. Three separate studies have shown that SLE
patients and their relatives have decreased numbers of eryth-
rocyte CR1 compared to normal controls [2]. In normal con-
trols, erythrocyte CR1 levels are high in 34%, moderate in 54%
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and low in 12%. By contrast, in SLE patients, erythrocyte CR!
levels are high in 5%, moderate in 42% and low in 53%. There
is evidence that the mode of inheritance of erythrocyte CR! is
through co-dominant genes [21.
Erythrocyte CR1 destruction. This is suggested by recent
studies by Ross and coworkers showing that erythrocyte-CR1
are diminished in SLE patients, in other patients with evidence
of circulating IC and in patients with autoimmune hemolytic
anemia [44]. Erythrocyte CR! may have been destroyed by
complement activation on the surface of the erythrocytes
because erythrocyte CR! levels varied inversely with erythro-
cyte membrane levels of C3d-g. These investigators also sug-
gested that erythrocyte CR1 may be lost from erythrocytes as
the IC are stripped from erythrocytes when the erythrocytes
traverse liver or spleen.
Erythrocyte-CRI occupancy. Many studies have shown that
in SLE patients, erythrocyte CR1 levels fall with disease
activity and rise with disease remission [2]. This suggests that
erythrocyte CR1 sites may be occupied by IC during disease
activity. During disease remission, these sites become once
again available. In support of this hypothesis, Taylor et al have
shown that IC are released from SLE erythrocytes when the
erythrocytes are incubated in EDTA serum [36]. Other inves-
tigators have not observed changes in the low erythrocyte CR!
levels of SLE patients with disease activity. However, it may
be that the identification of occupancy of erythrocyte CR1 may
be more complicated than simply enumerating erythrocyte CR!
with anti-CR! antibody or by assessing erythrocyte-IC binding
capacity using a preformed IC probe. For example, it is possible
that only certain clusters of CR! with a specific conformation
are able to bind pathogenic IC. If these clusters of erythrocyte
CR! represents only a small percent of the total number of CR!
in a population of erythrocytes, the occupancy of these specific
clusters of CR1 could be easily missed by methods which
simply enumerate total erythrocyte CR1 or assess the binding of
a single type of IC. Failing to detect occupancy of these specific
clusters of IC could be critical oversight especially if these
clusters of CR1 are those specifically responsible for the binding
of pathogenic IC. Erythrocyte CR! can also be inhibited by
anti-CRI auto-antibody. Wilson reported a single patient in
whom flare of the SLE was accompanied by the appearance of
anti CR! antibody and remission of the SLE was accomplished
by disappearance of the anti-CR1 antibody [45]. He suggested
that the anti-CR! antibody may have played a role in the SLE
flare.
Diminished erythrocyte CR1 levels have also been reported
in rheumatoid arthritis, malignancy and diabetes mellitus
[46—48]. In each of these conditions, there is evidence of
disturbed immune regulation and circulating IC have been
identified. It is possible that the abnormal erythrocyte CR!
could also be playing a role in the clinical expression of these
disorders.
Conclusion
There is now an abundance of evidence, based on in vitro
studies using the erythrocytes of human and other primates and
based on in vivo studies in nonhuman primates, indicating that
the erythrocyte-IC clearing and processing mechanism may
play a key role in the handling of IC in the circulation of
primates. Factors which perturb the clearing and/or processing
function of the erythrocyte may lead to the development of
glomerulonephritis and other IC-mediated diseases. The iden-
tification of the erythrocyte-IC clearing and processing mecha-
nism has provided what appears to be an important new clue in
the search to understand the pathogenesis and the means to
control IC-mediated disease in man.
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